132 related articles for article (PubMed ID: 28052221)
1. The Large Pharmaceutical Company Perspective.
Rosenblatt M
N Engl J Med; 2017 Jan; 376(1):52-60. PubMed ID: 28052221
[No Abstract] [Full Text] [Related]
2. [Progress for patients with osteoporosis].
MMW Fortschr Med; 2006 May; 148(20):56-7. PubMed ID: 16805195
[No Abstract] [Full Text] [Related]
3. The marketing of osteoporosis.
Napoli M
Am J Nurs; 2009 Apr; 109(4):58-61. PubMed ID: 19325320
[No Abstract] [Full Text] [Related]
4. Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.
Gromo G; Mann J; Fitzgerald JD
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890831
[TBL] [Abstract][Full Text] [Related]
5. [Osteoporosis treatment: choices and options].
Reginster JY
Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
[No Abstract] [Full Text] [Related]
6. [Alendronate].
Okazaki R
Clin Calcium; 2008 Oct; 18(10):1410-6. PubMed ID: 18830037
[TBL] [Abstract][Full Text] [Related]
7. [Bone density measurements after alendronate therapy?].
Schoppmeyer M
Med Monatsschr Pharm; 2015 May; 38(5):196-7; discussion 197. PubMed ID: 26364412
[No Abstract] [Full Text] [Related]
8. [Current research in adequate treatment by Osteoporosis Research Group].
Orimo H; Miyakawa N; Kuroda T
Clin Calcium; 2006 Sep; 16(9):1500-7. PubMed ID: 16951475
[TBL] [Abstract][Full Text] [Related]
9. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
[No Abstract] [Full Text] [Related]
10. [Bisphosphonate treatment in osteonecrosis of the femoral head].
Nishii T; Hashimoto J; Yoshikawa H; Miki H; Sugano N
Nihon Rinsho; 2007 Nov; 65 Suppl 9():537-41. PubMed ID: 18161162
[No Abstract] [Full Text] [Related]
11. [Treating with what? Therapy for how long?].
MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
[No Abstract] [Full Text] [Related]
12. [Patient compliance program aids therapy success].
MMW Fortschr Med; 2009 Mar; 151(11):47. PubMed ID: 19469207
[No Abstract] [Full Text] [Related]
13. [Prediction of vertebral strength using a CT based finite element method--clinical application in evaluation of the efficacy of alendronate].
Ohnishi I
Nihon Rinsho; 2009 May; 67(5):932-7. PubMed ID: 19432112
[TBL] [Abstract][Full Text] [Related]
14. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Wada S; Fukawa T; Kamiya S
Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
[TBL] [Abstract][Full Text] [Related]
15. [New proposal concerning alendronate reimbursement].
Halse J
Tidsskr Nor Laegeforen; 2010 May; 130(10):1021. PubMed ID: 20489801
[No Abstract] [Full Text] [Related]
16. Trial watch: Clinical trial cycle times continue to increase despite industry efforts.
Martin L; Hutchens M; Hawkins C
Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041
[No Abstract] [Full Text] [Related]
17. [Osteoporosis. Improving bone and muscle performance].
MMW Fortschr Med; 2010 Dec; 152(48):36. PubMed ID: 21222333
[No Abstract] [Full Text] [Related]
18. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
19. Is the increase in osteoporosis prevention a result of the audit?
Naunton M
Clin Neurol Neurosurg; 2006 Oct; 108(7):718-9. PubMed ID: 16621242
[No Abstract] [Full Text] [Related]
20. A study of codispensing with sodium alendronate in Australia.
Boyd IW; McEwen J; Calcino LJ
Br J Clin Pharmacol; 2006 Apr; 61(4):470-3. PubMed ID: 16542209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
